Entrada Therapeutics, Inc. (NASDAQ:TRDA) Given Average Rating of “Moderate Buy” by Brokerages

Entrada Therapeutics, Inc. (NASDAQ:TRDA) has received a consensus recommendation of “Moderate Buy” from the five brokerages that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, two have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $18.50.

A number of equities analysts have recently commented on TRDA shares. Wall Street Zen raised shares of Entrada Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Weiss Ratings reiterated a “sell (d)” rating on shares of Entrada Therapeutics in a research note on Monday, December 29th. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Entrada Therapeutics in a report on Wednesday, February 18th. Guggenheim raised shares of Entrada Therapeutics to a “strong-buy” rating in a research report on Wednesday, February 11th. Finally, Oppenheimer began coverage on shares of Entrada Therapeutics in a research report on Wednesday, January 28th. They set an “outperform” rating and a $21.00 target price for the company.

Insider Transactions at Entrada Therapeutics

In other news, COO Nathan J. Dowden sold 11,894 shares of the stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $13.05, for a total value of $155,216.70. Following the completion of the sale, the chief operating officer directly owned 198,588 shares of the company’s stock, valued at approximately $2,591,573.40. This represents a 5.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Kory James Wentworth sold 11,388 shares of the stock in a transaction that occurred on Tuesday, March 10th. The shares were sold at an average price of $13.02, for a total value of $148,271.76. Following the completion of the sale, the chief financial officer directly owned 121,510 shares of the company’s stock, valued at $1,582,060.20. This represents a 8.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 39,475 shares of company stock worth $508,069 over the last quarter. 8.11% of the stock is currently owned by corporate insiders.

Institutional Trading of Entrada Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of TRDA. Allspring Global Investments Holdings LLC lifted its stake in shares of Entrada Therapeutics by 9.8% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 17,495 shares of the company’s stock valued at $176,000 after buying an additional 1,560 shares during the period. Alliancebernstein L.P. grew its position in Entrada Therapeutics by 7.1% during the third quarter. Alliancebernstein L.P. now owns 24,320 shares of the company’s stock worth $141,000 after buying an additional 1,620 shares in the last quarter. Great Lakes Advisors LLC increased its stake in Entrada Therapeutics by 5.5% during the fourth quarter. Great Lakes Advisors LLC now owns 43,268 shares of the company’s stock valued at $445,000 after acquiring an additional 2,239 shares during the period. Intech Investment Management LLC increased its stake in Entrada Therapeutics by 15.7% during the second quarter. Intech Investment Management LLC now owns 17,702 shares of the company’s stock valued at $119,000 after acquiring an additional 2,397 shares during the period. Finally, Quadrature Capital Ltd raised its holdings in Entrada Therapeutics by 13.5% in the 4th quarter. Quadrature Capital Ltd now owns 20,318 shares of the company’s stock valued at $209,000 after acquiring an additional 2,424 shares in the last quarter. 86.39% of the stock is currently owned by institutional investors and hedge funds.

Entrada Therapeutics Price Performance

Shares of NASDAQ:TRDA opened at $12.69 on Friday. The stock has a market capitalization of $485.77 million, a P/E ratio of -3.67 and a beta of -0.12. The business has a 50-day moving average of $11.34 and a two-hundred day moving average of $8.94. Entrada Therapeutics has a fifty-two week low of $4.93 and a fifty-two week high of $13.65.

Entrada Therapeutics (NASDAQ:TRDA) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.94) EPS for the quarter, beating analysts’ consensus estimates of ($1.32) by $0.38. The business had revenue of $1.30 million for the quarter, compared to analyst estimates of $7.41 million. Entrada Therapeutics had a negative return on equity of 39.83% and a negative net margin of 565.48%. As a group, research analysts expect that Entrada Therapeutics will post 1.12 EPS for the current fiscal year.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.